Helixmith Completes Submission of Final Protocol for Phase 2a Clinical Trial of ALS Treatment
[Asia Economy Reporter Oh Ju-yeon] Helixmith announced on the 5th that it has completed the submission of the final protocol for the Phase 2a clinical trial to the U.S. Food and Drug Administration (FDA) to evaluate the safety and efficacy of Engensis (VM202) administered to patients with amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
